BTK and neoplasm: In the first case, Gunderson et al. showed that BTK inhibition, which impacts B cells and tumor-associated macrophages (TAMs), with the FDA-approved inhibitor ibrutinib restored T cell-mediated anti-tumor immunity in a model of PDAC and improves response to chemotherapy [111].